Clinical Trials Logo

Hepatic Metastasis clinical trials

View clinical trials related to Hepatic Metastasis.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06085976 Recruiting - Hepatic Carcinoma Clinical Trials

Efficacy and Safety of Octreotide in Laparoscopic Hepatectomy Surgery: Effect on Blood Loss, Need for Vasoactive Drugs, Transfusion Requirements.

Start date: August 14, 2023
Phase: Phase 2
Study type: Interventional

The goal of this double-blind clinical trial is to compare the efficacy of octreotide versus placebo in laparoscopic hepatectomy surgery in patients diagnosed with resectable hepatocarcinoma or liver metastases. The main questions it aims to answer are: - Decrease in intraoperative bleeding measured in ml of blood lost. - Decrease in the need for blood transfusion and use of intraoperative vasoactive drugs. Participants will receive octreotide or placebo after signing the informed consent form.

NCT ID: NCT06023966 Recruiting - Gastric Cancer Clinical Trials

A Clinical Prospective Study to Validate a Risk Scoring Model for the HMGC After Curative Surgery

Start date: September 1, 2023
Phase:
Study type: Observational

A previous study of investigators established a risk scoring model for the occurrence of postoperative hepatic metastases in patients who underwent curative gastrectomy directly without neoadjuvant therapy. In order to further validate the clinical applicability of abovementioned model, investigators designed this prospective study, which also included patients who received neoadjuvant therapy before surgery, with the aim of exploring the applicability of the risk scoring model to this group of patients.

NCT ID: NCT05027711 Recruiting - Hepatic Metastasis Clinical Trials

Magnetic Resonance-guided Adaptive Stereotactic Body Radiotherapy for Hepatic Metastases

MAESTRO
Start date: August 12, 2021
Phase: Phase 2
Study type: Interventional

Stereotactic body radiotherapy (SBRT) is an established local treatment method for patients with hepatic oligometastases. Liver metastases often occur in close proximity to radiosensitive organs at risk (OARs). This limits the possibility to apply sufficiently high doses needed for optimal local control. MR-guided radiotherapy (MRgRT) is expected to hold potential to improve hepatic SBRT by offering superior soft-tissue contrast for enhanced target identification as well as the benefit of daily real-time adaptive treatment. The MAESTRO trial therefore aims to assess the potential advantages of adaptive, gated MR-guided SBRT (MRgSBRT) compared to conventional SBRT at a standard linac using an ITV (internal target volume) approach (ITV-SBRT).

NCT ID: NCT01348256 Recruiting - Clinical trials for Colorectal Carcinoma

Study With Dendritic Cell Immunotherapy in Resected Hepatic Metastasis of Colorectal Carcinoma

Start date: November 2010
Phase: Phase 2
Study type: Interventional

In this randomized multicentric phase II study, patients with colorectal carcinoma with resectable hepatic metastasis will be randomized to treatment with dendritic cells or to observation, following conventional treatment with surgery and chemotherapy.